Market Trends of Global CAR T-Cell Therapy Industry
This section covers the major market trends shaping the Car T-Cell Therapy Market according to our research experts:
Multiple Myeloma is Expected to Observe a Significant Growth Over the Forecast Period
Multiple myeloma is cancer that forms in a type of white blood cell called a plasma cell. It is also known as Kahler's disease. The major factors fueling the market growth are the increasing burden of multiple myeloma, increasing research and development, and the implementation of strategic initiatives by the market players. For instance, as per Cancer Australia, In 2022, it is estimated that 2,625 new cases of multiple myeloma were diagnosed in Australia (1,540 males and 1,085 females). According to the same source, in 2022, it is estimated that a person has a 1 in 111 (or 0.90%) risk of being diagnosed with multiple myeloma by the age of 85 (1 in 94 or 1.1% for males and 1 in 135 or 0.74% for females).
The increasing number of approvals is also contributing to the market growth. For instance, in February 2022, the Janssen Pharmaceutical Companies of Johnson & Johnson reported the United States Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Similarly, in October 2022, the FDA granted accelerated approval to teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Thus, the market is expected to witness significant growth over the forecast period due to the above developments.
Hence, due to the rise in multiple myeloma cases, and the increase in product launches, the studied segment is expected to witness growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period
North America is expected to witness growth in the studied market owing to the increasing burden of chronic disorders such as cancer and autoimmune disorders, growth in research and development activities, and strong and established market players.
For instance, according to the American Cancer Society 2023 Cancer Statistics, the new number of cancer cases is estimated to be 1,958,310 in the United States in 2023. This estimation includes 1,010,310 number of males and 948,000 cases of females. Such a high number of cancer cases indicates the rising demand for CAR T-cell therapy in the country, thereby contributing to market growth. Additionally, several strategic initiatives the players implement contribute to market growth. For instance, in April 2022, Kite, a Gilead Company, reported the FDA-approved commercial production at the company's new CAR T-cell therapy manufacturing facility in Frederick, Maryland. The site will produce Kite's FDA-approved CAR T-cell therapy to treat blood cancer. Furthermore, clinical studies showing promising results in CAR T-cell therapies across the region are anticipated to increase the market demand. For instance, as per the June 2022 update from uOttawa, one of the first made-in-Canada CAR-T cell therapy for cancer showed promising results in the clinical trial. The trial is called Canadian-Led Immunotherapies in Cancer-01 (CLIC-01). It uses a different kind of cell manufacturing that opens the door to less expensive and more equitable treatment.
Moreover, the growing number of investments contributes to market growth. For instance, in June 2021, Blackstone reported that funds managed by Blackstone Life Sciences had committed USD 250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. and Cellex Cell Professionals GmbH, the parent company of GEMoaB GmbH, a clinical-stage cell therapy company.
Hence, due to the rise in cancer cases and the increase in clinical studies in CAR T -Cell therapies, North America is expected to witness growth over the forecast period.
